Edwards Lifesciences enters its July 23 earnings date with the Street more constructive than it has been all year — and the stock's 10% monthly rally giving bulls something to point to.
The analyst picture is unusually clean in its direction. Citigroup lifted its target to $110 from $101 this week, maintaining Buy. Evercore ISI raised to $100 from $93 on Monday. BTIG moved to $110 last week, also from $100. That makes three target increases in eight days, all from firms already holding positive ratings — a pattern of incremental confidence rather than fresh conviction, but notable in its consistency ahead of a print. The consensus mean target of roughly $98 sits just above the current price of $94.82, which keeps upside modest on a simple price-to-target basis. The hold camp, represented by Truist and Canaccord, has targets of $90 and $85 respectively — both below spot — suggesting a meaningful minority of the Street sees the recent rally as sufficient for now.
The bull case rests on TAVR volume momentum and the rapid commercial scaling of TMTT products, including Pascal and Evoque. Bulls see TMTT revenue guidance of $740–780 million for full-year 2026 as achievable, with TAVR growing 6–8%. The bear case is less about the top line and more about margins: adjusted operating margin came in at 23.7% in the most recent quarter versus a Street expectation of nearly 26%, driven by elevated SG&A. Bears also flag TAVR market maturation and rising competition as constraints on the stock's ability to sustain a premium multiple. The P/E of around 27.5x and EV/EBITDA near 21x are not stretched by historical medtech standards, but leave limited room for disappointment. EPS momentum ranks in the 43rd percentile on a 30-day basis — middling — while the 90-day read at 60 is firmer, suggesting the recent setup has improved but has not yet become a strong tailwind.
Short interest is low and not the story here. Roughly 2.2% of the free float is short — up about 17% over the past month in share terms, but from a small base. Borrowing costs have actually eased over the week to 0.47%, and availability is exceptionally loose at over 4,500% of outstanding short interest. There is essentially no lending-market tension. The short score of 32.3 has held in a tight range across the past two weeks, with no meaningful directional shift. Positioning looks neutral rather than charged.
Options sentiment has rotated quietly toward calls. The put/call ratio of 0.93 is running below its 20-day average of 0.99, and the z-score of -0.77 confirms a mild call-side tilt — modest in magnitude, but in the same direction as the analyst moves. For comparison, the PCR was consistently above 1.05 throughout June, so the recent shift is real even if not extreme. Among correlated peers, IDXX added 6.4% on the week and PODD added 2.4%, while GMED fell 6.1% — EW's 4.8% weekly gain sits closer to the outperforming names, consistent with the positive sentiment backdrop.
Insider activity is worth noting in tone rather than scale. All recent trades on record are sells — the CEO sold in June, a VP sold $2 million worth in May, and smaller routine disposals have continued into July. None are alarming in size relative to the company's float, and significance scores are low, but the absence of any buying into a 10% monthly rally is a quiet counterpoint to the bullish analyst chorus.
The July 23 print is now the focal point. The most recent earnings reactions from April show back-to-back next-day gains of around 3.2% and 3.4%, which set a constructive precedent — but the May print produced a 3.9% decline. The question heading into Q2 results is less about TAVR volumes, which the Street appears comfortable with, and more about whether the operating margin trajectory has stabilised after last quarter's miss.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
